Quality Agreements Between Pharmaceutical/Biopharmaceutical Companies and Their Contractors - - BioPharm International


Quality Agreements Between Pharmaceutical/Biopharmaceutical Companies and Their Contractors

BioPharm International

Sections, or subsections, of the QAG may require rewording, and sometimes a simple change of semantics may eliminate stumbling blocks in the negotiations. At other times, however, a change of language may be thought to alter the content substantially, and the sponsor or contractor may not be willing to make the modification. In such circumstances, further negotiation is required. Patience during initial efforts usually pays off in the long run, as extensive effort may be needed later on to correct mistakes made during the early negotiation process. The review process may begin via e-mail or fax, but at some point spoken negotiation will be required. In some cases a teleconference, coupled with Webex, may be a good option. Video conferencing, when available, might be sufficient to finalize QAG negotiations; however, final execution usually requires that representatives for both parties meet face-to-face to conclude the agreement. Although this meeting will not guarantee that conflict never surfaces, it can lower the probability. In some cases, a face-to-face negotiation is the only way to resolve some disagreements.

LEGAL REVIEW It is essential that a company put the final negotiated QAG draft through the legal review process; failure to do so can expose the company to potential liability. Often this review takes places when the business contract, to which the QAG has become an appendix or schedule, is reviewed. Just as qualified quality personnel should lend their expertise in the creation of the quality agreement, so must qualified legal counsel review the document with attention to potential liability as a result of the language used.

When a QAG is a stand-alone document and a company-approved format or template does not exist, the sponsor would be wise, once agreement has been reached between sponsor and contractor, to have the negotiated QAG undergo qualified legal review. In the event that a company template has already been approved by a company's quality and legal departments, the legal review is less critical. Nonetheless, it is still highly advisable to have the finalized QAG undergo legal review, especially to determine if any additions or deletions to the template could potentially cause legal liability to the company.

There should be a clear understanding by legal counsel of their role and function in the review process. When this understanding exists, the legal review process is likely to be relatively quick and not a stumbling block. It is important to note that a lack of such an understanding can cause unnecessary delays in finalizing QAGs, especially when they are stand-alone documents.

Legal personnel should not interpret GMPs nor change the context, unless there is a clear indication of language that can cause liability to the company in meeting the responsibilities of the agreement. They are not to write the QAG but are to look at it from a legal perspective to provide protection to the company. For example, ambiguous language that may create future difficulties can be mitigated in a proactive review by legal counsel. When the QAG is a stand-alone agreement, it is particularly important to bring it to legal counsel's attention for review.

The legal review process is intended to protect the company from potential liability as a result of the agreement. It is not, however, intended to change language, agreed to by both parties, that poses no liability threat to the company. It is also not intended to justify its existence by inserting unnecessary legal terms that may be intimidating to the sponsor or contractor.

CONCLUSION Conflict costs money! Far too often, easily preventable situations grow into irreconcilable differences between a sponsor and contractor that fail to benefit either party. Putting a sound QAG in place at the start of the business relationship can prevent later problems.

The lack of a QAG that covers areas such as deviation management and change management can lead to misunderstandings and conflicts. Formal agreements with contractors not only make good regulatory sense in ensuring GMP compliance, they also make good business sense and can potentially save the sponsor time and money. QAGs are, thus, an effective bridge to a successful future for companies in the pharmaceutical and biopharmaceutical industries.

Roby P. Blasini is a corporate consultant at a multi-national pharmaceutical company. Tel: 317.730.3129,

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here